Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carilex MedicalROCO:7726 34 EV-to-FCF is 16.55 as of Jul. 17, 2026, which is 13% below its 10-year median of 19.12. GuruFocus rates ROCO:7726 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Carilex Medical ranks better than 66.67% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Carilex Medical's Enterprise Value is NT$596.6 Mil.
Carilex Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$36.0 Mil. Therefore, Carilex Medical's EV-to-FCF for today is 16.55.
The historical rank and industry rank for Carilex Medical's EV-to-FCF or its related term are showing as below:
ROCO:7726'
s EV-to-FCF Range Over the Past 10 Years
Min: -243.17 Med: 19.12 Max: 38.35
Current: 16.5
During the past 6 years, the highest EV-to-FCF of Carilex Medical was 38.35. The lowest was -243.17. And the median was 19.12.
ROCO:7726's EV-to-FCF is ranked better than 66.67% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.635
vs ROCO:7726: 16.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Carilex Medical's PE Ratio (TTM) for today is calculated as:
Carilex Medical's share price for today is NT$31.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Carilex Medical EV-to-FCF Related Terms
Carilex Medical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Carilex Medical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Carilex Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carilex Medical EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Carilex Medical's EV-to-FCF falls into.
Carilex Medical's current Enterprise Value is NT$596.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$36.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carilex Medical (ROCO:7726) has a EV-to-FCF of 16.55 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Carilex Medical and its competitors. This is 13% below median its historical median of 19.12. According to the industry distribution chart, Carilex Medical ranks #138 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 33.3%.
Is Carilex Medical's EV-to-FCF too high?
Carilex Medical's current EV-to-FCF of 16.55 is 13% below median its 10-year median of 19.12. The Medical Devices & Instruments industry median EV-to-FCF is 23.64. Carilex Medical's value of 16.55 is 30% below this industry median. Based on the distribution chart, Carilex Medical ranks #138 out of 414 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Carilex Medical has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Carilex Medical ranks #138 out of 414 companies for EV-to-FCF. This puts Carilex Medical in the upper half of its industry. The industry median EV-to-FCF is 23.64. Carilex Medical's value of 16.55 is 30% below this benchmark. While the company's 10-year median is 19.12 vs. the industry median of 23.64, Carilex Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.64, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carilex Medical's current EV-to-FCF of 16.55 is 30% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Carilex Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carilex Medical's current EV-to-FCF is 16.55, which is 13% below median its own 10-year median of 19.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current EV-to-FCF of 16.55. The current EV-to-FCF is 16.55, which is 13% below median its 10-year median of 19.12 and 30% below the Medical Devices & Instruments industry median of 23.64. Carilex Medical's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current EV-to-FCF is 16.55 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
34GF Score
Get the complete analysis for ROCO:7726
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7726 has been successfully added to your 
